UPMC Inserm
Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH   Imprimer la page  
  Français   English  
Accueil
FHDH
A propos de la base
Principaux résultats
- RICE
- Publications
L'équipe
- Le GEC
- U943 (ex-U720)
Collaborations
Etudes cliniques
ONCOVIH
Autres études
EPIDERMAS
FranceCoag
Doctorants - post-docs
EPICLIN 2010

Liste des publications à partir des données
de la base FHDH

1992       1  

Guiguet M, Mary M, Costagliola D, Armengaud M, Cartier F, Micoud M, Mouton Y, Sobesky G, Valleron AJ.

-->  Trends in zidovudine prescription since 1987 in AIDS-free HIV-positive French patients attending university hospitals.
---->  AIDS. 1992 Nov;6(11):1405-6.
1995       2  
Costagliola D, Mary-Krause M.
-->  Can antiviral agents decrease the occurrence of Kaposi's sarcoma?
---->  Lancet. 1995 Aug 26;346(8974):578.
        3  
Mikol J, Costagliola D, Polivka M, Thiebaut JB, Trotot P.
-->  The epidemiology of cerebral lymphoma in AIDS
[Article in French]
---->  Neuroradiol. 1995 Sep;22(3):204-6.
1997       4  
Salhi Y, Costagliola D.
-->  Long-term nonprogression in HIV infection.
---->  J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Dec 15;16(5):409-11.
Comment on:
J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Mar 1;14(3):243-8.
1998       5  
Le Moing V, Bissuel F, Costagliola D, Eid Z, Chapuis F, Molina JM, Salmon-Ceron D, Brasseur P, Leport C.
-->  Decreased prevalence of intestinal cryptosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors.
---->  AIDS. 1998 Jul 30;12(11):1395-7.
        6  
Ray P, Antoine M, Mary-Krause M, Lebrette MG, Wislez M, Duvivier C, Meyohas MC, Girard PM, Mayaud C, Cadranel J.
-->  AIDS-related primary pulmonary lymphoma.
---->  Am J Respir Crit Care Med. 1998 Oct;158(4):1221-9.
        7  
Roux P, Ha MC, Brucker G, Costagliola D.
-->  Pneumocystis and pneumocystosis in Europe at the end of the 20th century.
---->  FEMS Immunol Med Microbiol. 1998 Sep;22(1-2):87-91.
1999       8  
Lievre L, Meyohas MC, Costagliola D.
-->  Impact of opportunistic diseases on survival in HIV-infected patients in France, 1992-1997.
---->  AIDS. 1999 Sep 10;13(13):1789-90.
        9  
Mary-Krause M, Billaud E.
-->  Impact of Kaposi's sarcoma in occurrence of opportunistic central nervous system disease.
---->  AIDS. 1999 Oct 1;13(14):1985-7.
        10  
Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M.
-->  Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups.
---->  AIDS. 1999 Oct 22;13(15):2075-82.
Comment in:
AIDS. 2000 Apr 14;14(6):754-6.
        11  
Tassie JM, Gasnault J, Bentata M, Deloumeaux J, Boue F, Billaud E, Costagliola D.
-->  Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors.
---->  AIDS. 1999 Oct 1;13(14):1881-7.
2000       12  
Bernillon P, Lievre L, Pillonel J, Laporte A, Costagliola D.
-->  Record-linkage between two anonymous databases for a capture-recapture estimation of underreporting of AIDS cases: France 1990-1993.
---->  Int J Epidemiol. 2000 Feb;29(1):168-74.
        13  
Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L.
-->  Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.
---->  Ann Intern Med. 2000 Sep 19;133(6):401-10.
Comment in:
Ann Intern Med. 2000 Sep 19;133(6):471-3.
        14  
Grabar S, Pradier C, Le Corfec E, Lancar R, Allavena C, Bentata M, Berlureau P, Dupont C, Fabbro-Peray P, Poizot-Martin I, Costagliola D.
-->  Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor.
---->  AIDS. 2000 Jan 28;14(2):141-9.
        15  
Mary-Krause M, Rabaud C, Jouan M, Obadia M, de la Blanchardiere A, Raffi F, May T.
-->  Mycobacterium avium complex disease in HIV seropositive patients: incidence and risk factors before and after the introduction of highly active antiretroviral treatments. [Article in French]
---->  Pathol Biol (Paris). 2000 Jun;48(5):495-504.
2001       16  
Abgrall S, Matheron S, Le Moing V, Dupont C, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV.
-->  Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis.
---->  J Acquir Immune Defic Syndr. 2001 Feb 1;26(2):151-8.
        17  
Abgrall S, Rabaud C, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.
-->  Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era.
---->  Clin Infect Dis. 2001 Nov 15;33(10):1747-55. Epub 2001 Oct 10. Comment in:
Clin Infect Dis. 2002 Apr 15;34(8):1161.
        18  
Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Chatelet FP, Katlama C, Charlotte F, Dupont B, Brousse N, Huerre M, Mikol J, Camparo P, Mokhtari K, Tulliez M, Salmon-Ceron D, Boue F, Costagliola D, Raphael M.
-->  Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy.
---->  Blood. 2001 Oct 15;98(8):2339-44
2002       19  
del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, Gastaut JA, Costagliola D, Rosenthal E; French Hospital Database on HIV Clinical Epidemiologic Group.
-->  Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus.
---->  J Infect Dis. 2002 Nov 1;186(9):1366-70. Epub 2002 Oct 11.
        20  
Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration.
-->  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
---->  Lancet. 2002 Jul 13;360(9327):119-29.
Erratum in:
Lancet 2002 Oct 12;360(9340):1178.
        21  
Tassie JM, Grabar S, Lancar R, Deloumeaux J, Bentata M, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV.
-->  Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection.
---->  J Acquir Immune Defic Syndr. 2002 May 1;30(1):81-7.
2003       22  
Abgrall S, Duval X, Joly V, Descamps D, Matheron S, Costagliola D; The Clinical Epidemiology Group from the French Hospital Database on HIV.
-->  Clinical and immunologic outcome in patients with Human Immunodeficiency Virus Infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
---->  Clin Infect Dis. 2003 Dec 1;37(11):1517-26. Epub 2003 Oct 29.
        23  
Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME; Antiretroviral Therapy Cohort Collaboration.
-->  Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies.
---->  Lancet. 2003 Aug 30;362(9385):679-86.
        24  
Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C, Plaisance N, Tissot-Dupont H, Boue F, Lang JM, Costagliola D.
-->  Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.
---->  J Clin Oncol. 2003 Sep 15;21(18):3447-53.
        25  
Kousignian I, Abgrall S, Duval X, Descamps D, Matheron S, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.
-->  Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.
---->  J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):50-7.
        26  
Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D; And the Clinical Epidemiology Group from the French Hospital Database.
-->  Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.
---->  AIDS. 2003 Nov 21;17(17):2479-86.
2004       27  
Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, Jung C, Mahamat A, Lang JM, Costagliola D.
-->  Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV.
---->  AIDS. 2004 Oct 21;18(15):2029-38.
        28  
Mary-Krause M, Herida M, Costagliola D, Lavole A, Cadranel J.
-->  In reply.
---->  J Clin Oncol. 2004 Apr 1;22(7):1349-50.
        29  
Phillips A, Ledergerber B, Lundgren J, Hogg B, D'Arminio Monforte A, Castelli F, Walker S, Staszewski S, Dabis F, Gazzard B, Saag M, Petoumenos K, Johnson M, Scullard G, Gill J, James I, Fischer M, Mussini C, Klein M, Costagliola D for the Collaboration o
-->  Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound.
---->  J Infect Dis. 2004 Aug 15;190(4):675-87.
2005       30  
d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger M; The Antiretroviral Therapy Cohort Collaboration.
-->  The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.
---->  Arch Intern Med. 2005 Feb 28;165(4):416-23.
        31  
Costagliola D, Potard V, Duvivier C, Pradier C, Dupont C, Salmon D, Duval X; French Hospital Database on HIV.
-->  Impact of newly available drugs on clinical progression in patients with virological failure after exposure to three classes of antiretrovirals.
---->  Antivir Ther. 2005;10(4):563-73.
        32  
Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E, Grabar S, Justice A, Staszewski S, Fatkenheuer G, Sterne JA; Antiretroviral Therapy Cohort Collaboration.
-->  Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America.
---->  Clin Infect Dis. 2005 Dec 15;41(12):1772-82.
        33  
Grabar S, Le Moing V, Goujard C, Egger M, Leport C, Kazatchkine MD, Weiss L, Costagliola D.
-->  Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection.
---->  J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):284-92.
        34  
Sabin C; Antiretroviral Therapy (ART) Cohort Collaboration.
-->  AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others?
---->  AIDS. 2005 Nov 18;19(17):1995-2000.
2006       35  
Abgrall S, Yeni PG, Bouchaud O, Costagliola D; the Clinical Epidemiology Group from the French Hospital Database on HIV.
-->  Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
---->  AIDS. 2006 Oct 24;20(16):2099-106.
        36  
Fardet L, Mary-Krause M, Heard I, Partisani M, Costagliola D; for the French Hospital Database on HIV.
-->  Influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response.
---->  HIV Med. 2006 Nov;7(8):520-529.
        37  
Fontaine C, Bonnard P, Mary-Krause M, Callard P, Pialoux G.
-->  Pulmonary pneumocystosis in a patient with greater than 500 CD4 cells/microl: a role for IL-2 therapy?
---->  AIDS. 2006 Aug 1;20(12):1680-1.
        38  
Grabar S, Abraham B, Mahamat A, Del Giudice P, Rosenthal E, Costagliola D.
-->  Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement.
---->  J Clin Oncol. 2006 Jul 20;24(21):3408-14.
        39  
Grabar S, Weiss L, Costagliola D.
-->  HIV infection in older patients in the HAART era.
---->  J Antimicrob Chemother. 2006 Jan;57(1):4-7.
        40  
Hernan MA, Lanoy E, Costagliola D, Robins JM.
-->  Comparison of dynamic treatment regimes via inverse probability weighting.
---->  Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):237-42.
        41  
Hogg R, May M, Phillips A, Costagliola D, Sterne J, Sabin C, De Wolf F, Ledergerber B, D’Arminio Monforte A, Justice A, Gill J, Fusco G, Staszewski S, Rockstroh J, Chêne G, Egger M.
-->  Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies.
---->  J Infect Dis. 2006 Sep 1;194(5):612-22.
        42  
Lanoy E, Mary-Krause M, Tattevin P, Dray-Spira R, Duvivier C, Fischer P, Obadia Y, Lert F, Costagliola D; Clinical Epidemiology Group of French Hospital Database on HIV Infection.
-->  Predictors identified for losses to follow-up among HIV-seropositive patients.
---->  J Clin Epidemiol. 2006 Aug;59(8):829-835. Epub 2006 May 30.
        43  
Lewden C, Jougla E, Alioum A, Pavillon G, Lievre L, Morlat P, Salmon D, May T, Chene G, Costagliola D; the Mortalite 2000 Study Group.
-->  Number of deaths among HIV-infected adults in France in 2000, three-source capture-recapture estimation.
---->  Epidemiol Infect. 2006 Dec;134(6):1345-52.
        44  
Lievre L, Deveau C, Gerbe J, Enel P, Tran L, De Castro N, Costagliola D, Meyer L; Primo Study Group; Clinical Epidemieology Group.
-->  Yearly number of patients diagnosed with primary HIV-1 infection in France estimated by a capture-recapture approach.
---->  AIDS. 2006 Nov 28;20(18):2392-5.
        45  
Mary-Krause M, Billaud E, Poizot-Martin I, Simon A, Dhiver C, Dupont C, Salmon D, Roudiere L, Costagliola D; Clinical Epidemiology Group of the French Hospital Database.
-->  Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy.
---->  AIDS. 2006 Aug 1;20(12):1627-35.
        46  
May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fatkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M; Antiretroviral Therapy. (ART) Cohort Collaboration
-->  HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.
---->  Lancet. 2006 Aug 5;368(9534):451-8.
2007       47  
Abgrall S, Yeni PG, Bouchaud O, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.
-->  Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
---->  Clin Infect Dis. 2007 Jan 1;44(1):120-7.
        48  
Guiguet M, Furco A, Tattevin P, Costagliola D, Molina JM, and the French Hospital Database on HIV Clinical Epidemiology Group.
-->  HIV-associated Isospora belli infection: incidence and risk factors in the French Hospital Database on HIV.
---->  HIV Med. 2007; 8(2): 124–130.
        49  
Lanoy E, Mary-Krause M, Tattevin P, Perbost I, Poizot-Martin I, Dupont C, Costagliola D and ANRS CO04 French Hospital Database on HIV Clinical Epidemiological Group.
-->  Frequency, determinants and consequences of delayed access to care for HIV infection in France.
---->  Antivir Ther. 2007;12(1): 89-96.
        50  
Mary-Krause M, Fichou J, Lanoy E, Lièvre L, Costagliola D et le Groupe d’épidémiologie clinique de l’ANRS CO4 FHDH.
-->  L’infection à VIH après 10 ans de traitements antirétroviraux actifs dans la base de données hospitalière française sur l’infection à VIH (ANRS CO4 FHDH).
---->  Bull Epidemiol Hebd 2007;46-47;394-397.
        51  
Potard V, Rey D, Mokhtari S, Frixon-Marin V, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D; French Hospital Database on HIV, ANRS C04
-->  First-line highly active antiretroviral regimens in 2001–2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.
---->  Antivir Ther. 2007;12(3):317-24.
        52  
Sterne J.A.C, May M, Sabin C,Phillips A,Costagliola D, Chêne, G, Justice A.C, de Wolf F, Hogg R, Battegay M, D’Arminio Monforte A, Fätkenheuer G, Staszewski S, Gill J, Egger M.
-->  Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients.
---->  J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):607-15.
2008       53  
Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, Porter K; CASCADE Collaboration.
-->  Changes in the risk of death after HIV seroconversion compared with mortality in the general population.
---->  JAMA. 2008; 300(1):51-9.
      54  
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group.
-->  Response to combination antiretroviral therapy: variation by age.
---->  AIDS. 2008; 22(12): 1463-1473.
      55  
Grabar S, Lanoy E, Allavena C, Mary-Krause M, Bentata M, Fischer P, Mahamat A, Rabaud C, Costagliola D.
-->  Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy.
---->  HIV Med 2008; 9:246-256.
        56  
Guiguet M, Mary-Krause M, Ename B, Grabar S, Costagliola D.
-->  Influence of control selection in nested case-control studies: the example of exposure to antiretroviral treatment (ART) and the risk of myocardial infarction (MI) in the French Hospital Database on HIV (FHDH-ANRS CO4).
---->  Pharmacoepidemiol Drug Saf 2008 17(5): 468-474.
        57  
Guiguet M, Porter K, Phillips A, Costagliola D, Babiker A, on behalf of the CASCADE Collaboration.
-->  Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART).
---->  The open AIDS journal 2008; 2: 3-9.
        58  
Harris RJ, Sterne JAC, Abgrall S, Dabis F, Reiss P, Saag M, Phillips AN, Chêne G, M Gill JM, Justice AC, Rockstroh J, Sabin CA, Mocroft A, Bucher HC, Hogg RS, D'Arminio Monforte A, May M, Egger M.
-->  Prognostic importance of anaemia in HIV-1 infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies in industrialized countries.
---->  Antivir Ther 2008;13(8): 959-967.
        59  
Hogg R, Lima V, Sterne J, Grabar S, Battegay M, Bonarek M, D'Arminio Monforte A, Esteve A, Gill J, Harris R, Justice A, Kitahata M, Lampe F, Mocroft A, Mugavero M, Staszewski S, Wasmuth JC, van Sighem A, Hayden A, Guest J, Egger M, May M.
-->  Life expectancy of persons on combination antiretroviral therapy (cART) in high-income countries.
---->  Lancet 2008;372:293-299.
        60  
Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, Hernández-Aguado I, Meyer L, Porter K, del Amo J; CASCADE Collaboration.
-->  Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women.
---->  Am J Epidemiol. 2008; 168(5):532-40.
        61  
Kousignian I, Abgrall S, Grabar S, Mahamat A, Teicher E, Rouveix E, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.
-->  Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency.
---->  Clin Infect Dis. 2008 Jan 15;46(2):296-304.
        62  
Mouala C, Houzé S, Guiguet M, Abboud P, Pialoux G, Viget N, Costagliola C, and Matheron S.
-->  Imported malaria in HIV-infected patients enrolled in the ANRS CO4 FHDH study.
---->  J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):55-60.
        63  
Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Huldrych F. Günthard HF, Dabis F, Robert Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Fiona Lampe F, Miró JM, Staszewski S, Sterne JAC.
-->  Does Short-term Virologic Failure Translate to Clinical Events in ARV-naïve Patients Initiating ART in Clinical Practice?
---->  AIDS 2008; 22(18):2481-92.
        64  
Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC, Porter K; CASCADE Collaboration.
-->  The effect of antiretroviral treatment of different durations in primary HIV infection.
---->  AIDS 2008; 22(18): 2441-50
        65  
Piketty C, Selinger-Leneman H, Grabar S, Duvivier C, Bonmarchand M, Abramowitz L, Costagliola D, Mary-Krause M on behalf of the FHDH-ANRS CO4.
-->  Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy.
---->  AIDS 2008; 22:1203–1211
        66  
Selinger-Leneman H, Matheron S, Mahamat A, Moreau J, Costagliola D, Abgrall S; for the Clinical Epidemiology Group of the French Hospital Database on HIV (ANRS CO4).
-->  Dual Nucleoside Reverse Transcriptase Inhibitor Therapy in the Combination Antiretroviral Therapy Era and Predictors of Discontinuation or Switch to Combination Antiretroviral Therapy.
---->  J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):206-211
        67  
Touloumi G, Pantazis N, Stirnadel H, Walker SA, Boufassa F, Vanhems P, Porter K, on behalf of the CASCADE Collaboration.
-->  Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice.
---->  J Acquir Immune Defic Syndr 2008; 49(5):492-498
2009       68  
Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro Murillo AM, Mocroft A, Bonnet F, Clifford G, Touloumi G, Miro JM, Chene G, Lundgren J, Egger M.
-->  Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy: European multi-cohort study.
---->  AIDS 2009; 23(15):2029-2037.
      69  
Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Chene G, Lundgren J, Egger M.
-->  Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: European multi-cohort study.
---->  Antivir ther 2009; 14(8): 1065-74.
        70  
Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D; ANRS AC11 Resistance Group; Cohort PRIMO ANRS CO 6; FHDH ANRS CO4 Study Groups.
-->  Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.
---->  AIDS 2009; 23(6):717-24.
      71  
Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D, on behalf of the FHDH ANRS CO4 and ANRS CO14.
-->  Interleukine 2 therapy does not increase the risk of Hodgkin’s or non Hodgkin’s lymphoma in HIV-infected patients; results from FHDH ANRS CO4.
---->  J Acquir Immune Defic Syndr 2009; 50(2): 206-214.
        72  
Grabar S, Selinger-Leneman H, Abgrall S, Pialoux G, Weiss L, Costagliola D.
-->  Prevalence and comparative characteristics of long-term non-progressors and HIV controller patients in the French Hospital Database on HIV.
---->  AIDS 2009 ; 23(9):1163–1169.
      73  
Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, on behalf of the Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort.
-->  Effect of immunodefi ciency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
---->  Lancet Oncology 2009; 10: 1152-1159.
        74  
Guiguet M, Kendjo E, Carcelain G, Abgrall S, Mary-Krause M, Tattevin P, Yazdanpanah Y, Costagliola D, Duval X, on behalf of the FHDH-ANRS CO4 Epidemiology Group.
-->  CD4 cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naïve patients with CD4 cell counts above 200/mm³.
---->  Antivir Ther 2009, 14(3): 451-457.
      75  
Hernan MA, McAdams M, McGrath N, Lanoy E, Costagliola D.
-->  Observation plans in longitudinal studies with time-varying treatments.
---->  Stat Methods Med Res 2009; 18(1): 27-52.
        76  
Lanoy E, Lewden C, Lièvre L, Tattevin P, Boileau J, Aouba A, Chêne G, Costagliola D, ANRS CO4 FHDH and Groupe d’Etude Mortalité 2000.
-->  How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French Hospital Database on HIV, Mortalité 2000 Survey and death certificates.
---->  HIV Med 2009; 10(4): 236-245.
      77  
Lanoy E, May M, Mocroft A, Phillips A, Justice A, Chêne G, Furrer H, Sterling T, D'Arminio Monforte A, Force L, Gill J, Harris R, Hogg RS, Kitahata M, Rockstroh J, Saag M, Staszewski S, de Wolf F, Sterne JAC, Costagliola D.
-->  Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.
---->  AIDS 2009; 23(16):2199-2208.
        78  
Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, Hamouda O, Prins M, Walker AS, Porter K, Sabin C, Chêne G on behalf of the CASCADE Collaboration.
-->  Non-AIDS defining deaths and immunodeficiency in the era of combination antiretroviral therapy. CASCADE, 1996-2006.
---->  AIDS 2009; 23(13):1743-1753.
      79  
Mocroft A, Sterne J, Egger M, May M, Grabar S, Hansjakob Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d’Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M.
-->  Variable impact on mortality of AIDS defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.
---->  Clin Infect Dis 2009; 48(8): 1138-115.
        80  
Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, J. Mugavero MJ, D'Arminio Monforte A, Sabin C, Podzamczer D, Fätkenheuer G, Staszewski S, Gill J, Sterne JAC.
-->  Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.
---->  J Acquir Immune Defic Syndr 2009; 52(3):357-363.
      81  
Mouala C, Guiguet M, Houzé S, Damond F, Pialoux G, Viget N, Costagliola D, Le Bras J, Matheron S, on behalf of the FHDH-ANRS CO4 Clinical Epidemiology Group.
-->  Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts<350/mm3.
---->  AIDS 2009; 23(15): 1997-2004.
        82  
Potard V, Weiss L, Lamontagne F, Rouveix E, Beck-Wirth G, Drogoul-Vey MP, Faouzi Souala M, Costagliola D and the French hospital database on HIV, ANRS CO4.
-->  Trends in post-infection CD4 cell counts and Plasma HIV-1 RNA levels in HIV-1-infected patients in France between 1997 and 2005.
---->  J Acquir Immune Defic Syndr 2009; 52(3):442-426.
      83  
Sterne JAC, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Jönsson Funk M, Geskus R, Gill J, Dabis F, Miró JM, Justice A, Ledergerber B, Fätkenheuer G, Hogg R, D’Arminio Monforte A, Saag M, Smith C, Staszewski S, Egger M, Cole SR (When to start consortium).
-->  Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
---->  Lancet 2009; 373(9672): 1352-1363.
        84  
Zwahlen M, Hogg R, May M, Costagliola D, Lewden C, Justice A, von Wyl V, Egger M.
-->  Mortality of HIV-infected patients starting potent antiretroviral therapy: Comparison with general population in eight countries.
---->  Int J Epidemiol 2009; 38(6): 1624-1633.
2010       85  
Ray M, Logan R, Sterne JAC, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA.
-->  The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.
---->  AIDS 2010; 24: 123-137.
Adresse Mentions légales Extranet Administration